Comparative Pharmacology
Head-to-head clinical analysis: FLUOXETINE POSTPARTUM SAFETY versus LUVOX CR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUOXETINE POSTPARTUM SAFETY versus LUVOX CR.
Fluoxetine-Safety-Postpartum vs LUVOX CR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake in the synaptic cleft, potentiating serotonergic activity in the CNS.
Selective serotonin reuptake inhibitor (SSRI); increases serotonin availability in the synaptic cleft by blocking serotonin reuptake transporters (SERT).
20 mg orally once daily, initially; may increase after several weeks to a maximum of 80 mg/day. Administer in the morning.
100-300 mg orally once daily at bedtime
None Documented
None Documented
Fluoxetine: 4-6 days (acute), 4-6 weeks (chronic); norfluoxetine: 4-16 days. Steady-state achieved after 2-4 weeks.
The terminal elimination half-life is approximately 15-20 hours after single doses and 17-26 hours after multiple doses. This supports once-daily dosing, with steady-state achieved within 1-2 weeks.
Renal (80% as metabolites, 10% as unchanged drug) and fecal (15%)
Approximately 94% of a dose is excreted in urine, with less than 4% as unchanged drug. The remainder is eliminated in feces. Renal excretion of metabolites accounts for the majority of elimination.
Category A/B
Category C
SSRI Antidepressant
SSRI Antidepressant